AstraZeneca Pharma India (NSE:ASTRAZEN) Momentum Rank: 5 (As of Sep. 09, 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
83 GF Score
Price ₹6,876.50
GF Value ₹11,514.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Momentum Rank?

AstraZeneca Pharma India NSE:ASTRAZEN +0.01% 83 Momentum Rank is 5 as of Sep. 09, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 83/100 and a GF Value™ of ₹11,514.49 (Possible Value Trap). The stock has 6 warning signs investors should review.

AstraZeneca Pharma India has the Momentum Rank of 5.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

AstraZeneca Pharma India Momentum Rank Related Terms

NSE:ASTRAZEN vs ZTS: Momentum Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Pharma India Momentum Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Momentum Rank distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Momentum Rank falls into.


NSE:ASTRAZEN
83GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 5 mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Momentum Rank of 5 as of Sep. 09, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on AstraZeneca Pharma India and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, AstraZeneca Pharma India's Momentum Rank has ranged from 1.00 to 10.00.
Is AstraZeneca Pharma India's Momentum Rank too high?
AstraZeneca Pharma India's current Momentum Rank of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, AstraZeneca Pharma India has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Momentum Rank compare to ZTS?
AstraZeneca Pharma India's Momentum Rank of 5 can be compared against companies in the Drug Manufacturers industry. Historically, AstraZeneca Pharma India's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Drug Manufacturers company?
A good Momentum Rank depends on the Drug Manufacturers industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Momentum Rank is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,514.49, compared to a current price of ₹6,876.50 — trading 40.3% below its estimated fair value. The current Momentum Rank is 5, which is 17% below median its 10-year median of 6.00. AstraZeneca Pharma India's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Momentum Rank is 5 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹6,876.50 is trading 40.3% below its estimated GF Value™ of ₹11,514.49. GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.

Key valuation signals for NSE:ASTRAZEN:

  • Momentum Rank: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: ₹11,514.49 vs. price of ₹6,876.50 (40.3% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
83GF Score

Get the complete analysis for NSE:ASTRAZEN

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,876.50
Price
₹11,514.49
GF Value